<< Back To Search

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
This study will test two drugs, isatuximab and lenalidomide, on patients who have undergone a type of stem cell transplant called Autologous Stem Cell Transplant. Doctors will give these drugs to patients who still have small amounts of cancer cells in their body, called MRD-positive. The goal is to see if the drugs can help keep the cancer from coming back.
*Third Opinion AI Generated Synopsis

Trial Summary
This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?